ing for MDRGNRs are desper ately needed.
Incorporating these fundamen tal prevention and control prac tices into the daily life of the hospital is difficult, as demon strated by persistently low rates of adherence even in the coun try's most prestigious institutions. The Department of Health and Human Services and many orga nizations have invested heavily in programs aimed at improving per formance, but hospitals often ap proach each infection individually rather than redesigning frontline systems to facilitate adherence to best practices -for example, in corporating a set of critical prac tices, such as timely removal of in vasive devices and "deescalation" of antibiotic treatment (including narrowing or discontinuing anti biotics once culture results are available), into a bedside check list. Multidisciplinary care path ways can incorporate standing order sets, checklists, and prompts (such as alerts to consider "seda tion vacation" for ventilated pa tients) that can facilitate not only adherence but also realtime data collection and feedback that re inforce social norms. Enhanced data collection can be accom plished through "random audits" 4 that target one key aspect of evi dencebased care at least weekly on rounds, with the team check ing adherence on a simple form at each bedside and sharing a tally and strategies for improve ment at the end of rounds. This data collection should be a seam less part of work, not extra labor performed by someone else.
Even fastidious adherence to evidencebased practice does not guarantee immunity from MDR GNR outbreaks. Although relative ly rare, these outbreaks require ongoing vigilance, rapid epidemi ologic investigation, and prompt response. 5 Commonsource out breaks caused by contaminated solutions or equipment still oc cur despite advances in steriliza tion and disinfection, elimination of multidose containers, and pro cedures designed to minimize contamination during use. New resistant pathogens may emerge suddenly and escape the growing global surveillance network, arriv ing at the hospital door unher alded. But if hospitals develop reliable, evidencebased systems to minimize the MDRO threat, they will be able to refocus on developing innovative approaches to intercepting and mitigating new dangers. I n the 1970s, the Food and Drug Administration (FDA) de veloped regulatory pathways for a number of active drug ingredi ents that were on the market but had not been approved by the FDA. Antiseptic drug products fall into one class of drugs that was included in the regulations that resulted from the expert re views of the 1970s. At the time, it was assumed that antiseptic drug products were free of mi crobial contamination because of their pharmacologic activity. The need for sterile manufacture for these products was therefore not considered. In recent years, how ever, there have been published reports linking outbreaks of in fection to antiseptic products that were contaminated with micro bial organisms, and some prod ucts have been recalled for that reason. The FDAapproved indications for these products include "for preparation of the skin prior to surgery," "for preparation of the skin prior to an injection," and "helps reduce bacteria that poten tially can cause skin infection." Offlabel uses (e.g., catheter main tenance) are prevalent in clinical practice and have been incorpo rated into practice guidelines from the Centers for Disease Control and Prevention (CDC). The nonprescription status of top ical antiseptic products allows for direct access by consumers, although these products are mar keted predominantly to health care facilities. Given their wide use, evidence that topical anti septic products may become con taminated with microbial organ isms (during manufacture or use) -and that they can cause infec tion at sites of injection, sur gery, or existing wounds -has raised concerns.
Outbreaks associated with the use of contaminated antiseptic products (see table) have been re ported in journals 1 and to the CDC. 2, 3 Clinical infections asso ciated with a variety of approved products have been reported to the FDA as well, and a number of product recalls have ensued. 4 The reported outcomes range from localized infections at injection sites to systemic infections result ing in death. The reports impli cate all commonly used antisep tic categories, including alcohol, iodophors, chlorhexidine gluco nate, and quaternary ammonium products. Some potentially patho genic organisms, such as Bacillus cereus, Burkholderia cepacia, Pseudo monas aeruginosa, and Serratia mar cescens, have been implicated in more than one outbreak.
Although the scope of noso comial infections associated with contaminated antiseptic products is difficult to assess, it is most likely broader than has been in dicated by postmarketing reports and the medical literature. Sev eral factors may limit the identi fication of infections related to antiseptic products. Health care providers may not consider these products as a potential source of postprocedural infection because they assume that antiseptic prop erties preclude microbial surviv al. Cases of contamination might be underreported, since epidemi ologic investigation and infection workups require a high index of suspicion on the part of the treat ing clinician. In addition, single use containers are typically dis carded at the conclusion of a surgical procedure, so the resid ual product may not be available for investigation when an infec tion becomes apparent. Confir mation of contamination often requires the testing of other units from the same manufactur ing lot as the suspect product; however, contamination may not occur consistently within a lot, confounding the infection work up. Because the background rate of postoperative infection varies with the type of procedure, pa tient demographic characteris tics, and hospital environment, it may be difficult to detect an in crease in the rate of postproce dural infections stemming from contaminated antiseptic products. Although the CDC collects data on surgicalsite infections on the basis of diagnoses at hospital discharge, infections treated in ambulatory settings may not be captured. Finally, the reporting of nosocomial infections to reg ulatory agencies is voluntary, and medicolegal considerations and time constraints may deter hos pitals and health care providers from reporting.
Contamination of antiseptic drug products may occur either during manufacturing (intrinsic contamination) or during ma nipulations by the end user (ex trinsic contamination). Extrinsic contamination can arise from di lution of the product with non sterile water or from storage in nonsterile containers. Users should also be aware that microbial con tamination can occur when they are opening containers or dilut ing and storing solutions under nonsterile conditions. The period during which a container, once opened, can remain safe from extrinsic contamination is un known. Awareness on the part of users may reduce the likelihood that multidose antiseptic prod ucts will become contaminated. In August 2009, the FDA Phar maceutical Science and Clinical Pharmacology Advisory Commit tee considered whether sterile conditions of manufacture should be mandated for topical antisep tic products intended for use on nonintact skin. 5 Advisory com mittee members discussed the uncertainties of the costs and benefits and noted that the ex tent of the clinical problem was unclear. The committee also raised concerns about whether potential requirements for sterile manu facture might adversely affect the purity and quality of active ingre dients or the integrity of product packaging. The committee did not come to a final decision, but they observed that the labels of two foreignmade topical chlorhexidine gluconate products claimed that they had been manufactured un der sterile conditions. The FDA is continuing to eval uate the issues surrounding a re quirement for the sterile manu facture of antiseptic products. It is important that health care pro viders be aware that topical anti septic products, if contaminated, pose a risk of infection and that particular microbes isolated from clinical specimens have been traced to the contamination of such products (see table) . The isolation of unusual organisms (e.g., Bacillus cereus) after the use of topical antiseptic products should trigger an investigation of possible contamination stem ming from an antiseptic product.
We also encourage the prompt reporting of pertinent findings to the FDA to help us better un derstand the causes and scope of microbial contamination in anti septic products. Finally, the FDA is holding a public hearing, scheduled for December 12 and 13, 2012, and invites input con cerning the microbial contami nation of these products.
Editor's note: Further information about the FDA hearing on microbial contamination of topical antiseptic products may be found at www.fda.gov/Drugs/NewsEvents/ucm319621 .htm.
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